TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11454372
Drug: Low-dose techniques
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose techniques
Study: 11454372
Drug: Low-dose infusion
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose infusion group
Study: 9498439
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A supplementation (60-mg retinol equivalent, 200,000 IU)
Study: 7989683
Drug: Infiltration anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anesthesia administered into the incised edges of the wound
Study: 7989683
Drug: Infiltration anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anesthesia administered into the skin surrounding the wound
Study: 2563896
Drug: Intravenous metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous metoprolol (15 mg immediately, followed by oral metoprolol)
Study: 2563896
Drug: Deferred oral
Normalized name: ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Deferred oral beta-blockade (started on day 6)
Study: 25556976
Drug: Aripiprazole once-monthly
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aripiprazole once-monthly (AOM) 400 mg
Study: 25556976
Drug: Oral aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral aripiprazole (6-24 mg/day)
Study: 17117016
Drug: Valacyclovir 500
Normalized name: valacyclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir 500 mg twice a day
Study: 9272926
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) via pressurized metered-dose inhaler (pMDI)
Study: 24335055
Drug: 800 IU
Normalized name: Vitamin E 800 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 IU (20 μg) vitamin D₃
Study: 24335055
Drug: 2000 IU
Normalized name: D 2000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 IU (50 μg) vitamin D₃
Study: 24335055
Drug: 4000 IU
Normalized name: Cholecalciferol 4000 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 IU (100 μg) vitamin D₃
Study: 23099311
Drug: Implicit dosage
Normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Implicit dosage interval (6 ML by mouth every 12 hours)
Study: 23099311
Drug: Explicit dosage
Normalized name: Empliciti
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Explicit dosage interval (6 ML by mouth at 7 AM and 7 PM)
Study: 20145273
Drug: High-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose imatinib (800 mg/day for 6 months followed by 400 mg/day as maintenance therapy)
Study: 22511495
Drug: Standard-dose imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose imatinib (400 mg/day)
Study: 10664054
Drug: dimenhydrinate suppositories
Normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: dimenhydrinate suppositories
Study: 8878241
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg on Day 1, followed by 5 mg/kg once daily for 4 days)
Study: 8878243
Drug: Amoxicillin/clavulanate (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (approximately 40 mg/kg/day in 3 divided doses for 10 days)
Study: 1985163
Drug: Simultaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous continuous infusions of MTX and VM‐26
Study: 1985163
Drug: Sequential continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential continuous infusions of MTX and VM‐26
Study: 31234639
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors and β-blockers
Study: 28691885
Drug: Fitusiran (0.225,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran (0.225, 0.45, 0.9, or 1.8 mg/kg or fixed dose of 80 mg, once monthly)
Study: 28691885
Drug: Fitusiran (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran (0.03 mg/kg, single subcutaneous injection)
Study: 28691885
Drug: Fitusiran (0.015,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran (0.015, 0.045, or 0.075 mg/kg, once weekly)
Study: 28691885
Drug: Fitusiran (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran (once monthly)
Study: 23364237
Drug: Sarpogrelate (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sarpogrelate (100 mg, tid)
Study: 28898204
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg, qd)
Study: 12112177
Drug: Sertraline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100 mg OD)
Study: 10025743
Drug: Atopy Patch
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopy Patch Test (APT) with 3000 to 10,000 PNU/g of Dermatophagoides pteronyssinus, cat dander, grass, birch, and mugwort pollen allergen extracts in petrolatum
Study: 8703659
Drug: Inhaled magnesium
Normalized name: Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled magnesium sulphate (0, 90, 135, 180, 360 mg)
Study: 16444382
Drug: Norfloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (400 mg daily)
Study: 101316
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (800 mg/day for 1 week or a single dose of 1.0 g by mouth)
Study: 101316
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate (by inhalation)
Study: 7058674
Drug: Arginine aspartate
Normalized name: Arginine aspartate
DrugBank: Arginine aspartate (DB15993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arginine aspartate (250 mg/dg/day for one week)
Study: 26965174
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU); n=89
Study: 25253174
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg/bid)
Study: 22731240
Drug: Ondansetron in
Normalized name: ondansetron Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron in combination with dexamethasone
Study: 20831698
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg q.i.d.
Study: 18159905
Drug: Potent topical
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potent topical steroids
Study: 16129209
Drug: Low-calcium session
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-calcium session (L-HF) with calcium ion concentration of 2.5 mEq/L (1.25 mmol/L)
Study: 16129209
Drug: High-calcium session
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-calcium session (H-HF) with calcium ion concentration of 3.5 mEq/L (1.75 mmol/L)
Study: 11815895
Drug: Oral antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antioxidant micronutrient mixture (beta-carotene 18 mg/day, vitamin C 750 mg/day, vitamin E 600 mg/day)
Study: 10070054
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 4 mmol/l
Study: 10070054
Drug: Blood glucose
Normalized name: Blood Glucose Book
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood glucose concentration at 9 mmol/l
Study: 1849133
Drug: OKY-046 (thromboxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY-046 (thromboxane A2 synthetase inhibitor)
Study: 31416357
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation plus platelet inhibition (OAC+PI)
Study: 26917112
Drug: ATV/r 300/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATV/r 300/100 mg once daily
Study: 21842159
Drug: Ayahuasca (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ayahuasca (0.75 mg DMT/kg bodyweight)
Study: 19398067
Drug: 3g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3g of oral Myelophil per day
Study: 17124249
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment delivered in hospital (ATH)
Study: 12037070
Drug: Indinavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir treatment arm
Study: 12037070
Drug: Dual-nucleoside treatment
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-nucleoside treatment arm
Study: 12037070
Drug: Indinavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir treatment arm (plasma HIV-1 RNA <500 copies/ml)
Study: 12037070
Drug: Indinavir treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indinavir treatment arm (plasma HIV-1 RNA >or=500 copies/ml)
Study: 12037070
Drug: Samples with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Samples with plasma RNA levels <50 copies/ml
Study: 12016904
Drug: roxithromycin dispersible
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin dispersible tablet (formulation A)
Study: 12016904
Drug: conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: conventional tablet (formulation B)
Study: 2173646
Drug: No drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: No drug therapy between shocks
Study: 210476
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg chlorpromazine
Study: 3330184
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg chlorpromazine
Study: 11421842
Drug: Tramadol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1.5 mg kg(‐1)
Study: 16525746
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium phosphate (Fleet)
Study: 16525746
Drug: Picoprep (sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Picoprep (sodium picosulfate-based preparation)
Study: 12525827
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered as a 90- to 110-μg/kg bolus dose every second hour.
Study: 12525827
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered for major surgery and life-threatening bleeding.
Study: 12525827
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) with longer intervals between doses after the first 24 hours.
Study: 12525827
Drug: Recombinant activated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) at higher doses in in vitro experiments.
Study: 10770171
Drug: Physiological study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological study (hydrocortisone infusion for 48 h in a pulsatile and diurnal pattern)
Study: 10770171
Drug: Constant study
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant study (same total dose of hydrocortisone as physiological study, but with pulses of equal magnitude spaced evenly)
Study: 10770171
Drug: Reversed study
Normalized name: Revertased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reversed study (same total dose of hydrocortisone, but with diurnal pattern shifted 12 h)
Study: 10770171
Drug: Baseline study
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline study (saline infusion for 48 h)
Study: 8851456
Drug: 10-mg CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-mg CR oxycodone tablet every 12 hours for 4 days
Study: 8851456
Drug: 5 mL
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mL of 1-mg/1 mL IR oxycodone solution every 6 hours for 4 days
Study: 6726654
Drug: Imipramine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine with cimetidine (300 mg every 6 hr)
Study: 22009369
Drug: Intravenous bolus
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of lipopolysaccharide (LPS, 4 ng/kg)
Study: 16767525
Drug: 250 microg
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 microg daily nasal hPTH(1-34) spray for 3 months
Study: 16767525
Drug: 500 microg
Normalized name: Etizolam 500 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 microg daily nasal hPTH(1-34) spray for 3 months
Study: 16767525
Drug: 1,000 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 microg daily nasal hPTH(1-34) spray for 3 months
Study: 16767525
Drug: Daily supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplements of 300 mg calcium and 200 IU vitamin D(3)
Study: 14517200
Drug: Sirolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (10 mg oral dose) alone
Study: 14517200
Drug: Sirolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (10 mg oral dose) administered 4 hours after CsA (300 mg oral dose)
Study: 14517200
Drug: Cyclosporine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (300 mg oral dose) alone
Study: 14517200
Drug: Sirolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (10 mg oral dose)
Study: 15644588
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 mg/day)
Study: 9200296
Drug: Observation (conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (conservative treatment)
Study: 7827590
Drug: Indole-3-carbinol (I3C)
DrugBank: Indole-3-carbinol (DB12881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indole-3-carbinol (I3C) 400 mg/day for 3 months
Study: 7827590
Drug: Alpha-cellulose 20
Normalized name: ALPHA CELLULOSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-cellulose 20 g/day for 3 months
Study: 3402101
Drug: Water instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water instillation (1 drop 0.05 ml, 2 drops 0.1 ml, or no water)
Study: 26232311
Drug: 2-L polyethylene
Normalized name: Iron(2+) L-ascorbate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-L polyethylene glycol-citrate-simethicone plus 2-day bisacodyl
Study: 26232311
Drug: 4-L polyethylene
Normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-L polyethylene glycol
Study: 24827127
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 2.0 mg/m² on day 1 with erlotinib 150 mg on days 2-16 (21-day regimen)
Study: 24827127
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate 1.4 mg/m² on days 1 and 8 with erlotinib 150 mg on days 15-28 (28-day regimen)
Study: 20102890
Drug: Quinapril 40
Normalized name: quinapril 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril 40 mg/day orally (n = 43)
Study: 18600119
Drug: Effective nursing
Normalized name: PAD,NURSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effective nursing interventions conducted daily for 45 to 60 minutes after the 7th to 10th day of chemotherapy
Study: 12177105
Drug: Motexafin gadolinium
Normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motexafin gadolinium (5.0 mg/kg/d for 10 days) administered before each radiation treatment
Study: 1472933
Drug: Busulfan (conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (conventional treatment)
Study: 1472933
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (hydrea or busulfan)
Study: 29404931
Drug: Trial formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial formulation
Study: 24779438
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment and care (control group)
Study: 15640477
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg calcium carbonate/d)
Study: 12047486
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of ayahuasca (0.6 mg DMT kg(‐1) body weight)
Study: 12047486
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of ayahuasca (0.85 mg DMT kg(‐1) body weight)
Study: 8479131
Drug: Ketoacid supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoacid supplement (KA)
Study: 8479131
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid supplement (AA)
Study: 15173777
Drug: Dipyridamole administration
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole administration
Study: 31597315
Drug: Quercetin (CM+Q
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quercetin (CM+Q group), administered orally for 3-5 days before catheterization.
Study: 25362220
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - received 1000 mL of normal saline before CAA
Study: 22395527
Drug: Lurasidone (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40-120 mg)
Study: 19900349
Drug: Risperidone (2-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2-6 mg)
Study: 18625622
Drug: 8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg/kg tocilizumab
Study: 18625622
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg tocilizumab
Study: 11279947
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg per day
Study: 7739706
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg per day
Study: 1962901
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily according to body weight classes (55 to 65 Factor‐Xa inhibitory U/kg) for 14 days
Study: 116298
Drug: Naloxone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (20 mg IV)
Study: 21200337
Drug: PDA with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDA with daily tailored feedback message (PDA + FB)
Study: 17905915
Drug: Syntactic-semantic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syntactic-semantic therapy
Study: 17905915
Drug: Semantic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semantic therapy
Study: 26673292
Drug: Gene engineering
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene engineering technologies of angiogenesis stimulation as an independent method of treatment in comprehensive conservative therapy (80 patients)
Study: 26673292
Drug: Gene engineering
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene engineering technologies of angiogenesis stimulation as comprehensive treatment in combination with revascularizing operations (80 patients)
Study: 12808401
Drug: Nonpreserved lubricants,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpreserved lubricants, topical steroidal and nonsteroidal anti-inflammatory agents, punctal plugs for aqueous-deficient dry eye, mechanical removal of filaments, hypertonic saline, mucolytic agents, and bandage contact lenses.
Study: 12808401
Drug: Alternate medications
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate medications or additional measures to manage the tear film and ocular surface.
Study: 1610631
Drug: Demand top-ups
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand top-ups of 0.25% plain bupivacaine 10 ml
Study: 1610631
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of 0.125% plain bupivacaine 10 ml h‐1
Study: 1610631
Drug: Patient-controlled extradural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled extradural analgesia (PCEA) delivering 3-ml boluses of 0.25% bupivacaine
Study: 3968329
Drug: Bitolterol aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bitolterol aerosol (three sprays, 1.11 mg)
Study: 3968329
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol (two sprays, 180 mcg)
Study: 27444660
Drug: ONO‐6950 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐6950 (200 mg)
Study: 22160854
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily plus TMZ 150 mg/m(2)/day for 5 days every 28 days (NEIAEDs)
Study: 22160854
Drug: Everolimus (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (various doses) plus TMZ (150 mg/m(2)/day) (EIAEDs)
Study: 21055801
Drug: 1 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/day paricalcitol
Study: 21055801
Drug: 2 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg/day paricalcitol
Study: 10557953
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low doses of estrogen combined with vitamin D and calcium
Study: 10557953
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy with very low doses of estrogen
Study: 8556189
Drug: Dofetilide (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dofetilide (0.1 to 8.0 ng/mL)
Study: 1683403
Drug: Cabergoline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 1.0 mg
Study: 1683403
Drug: Cabergoline 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.75 mg
Study: 1683403
Drug: Cabergoline 0.5
Normalized name: cabergoline 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabergoline 0.5 mg
Study: 17316466
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of hydrocortisone